Aurora Leso

Aurora Leso

Auto-generated profile, based on publicly available information

Aurora Leso

Legnaro National Laboratories, National Institute for Nuclear Physics, INFN-LNL, Viale dell'Università 2, 35020 Legnaro, Italy; Department of Physics and Earth Science, University of Ferrara, Via G. Saragat 1, 44121 Ferrara, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Applied Radiation and Isotopes
Verified
Journal Article
Open access
ADA. Donzella
A. Donzella
ALA. Leso
A. Leso
AAA. Arzenton
A. Arzenton
GBG. Bonomi
G. Bonomi
SBS. Bortolussi
S. Bortolussi
AAA. Andrighetto
A. Andrighetto
The ISOLPHARM project of the INFN aims to study the properties of the 111Ag β- emitter as a promising core for novel radiopharmaceuticals. 111Ag will be produced at the SPES facility of the Legnaro National Laboratories, with high specific activity and remarkable yields, exploiting the ISOL technique. This work presents Monte Carlo dosimetry calculations at cellular level to assess the therapeutic potential of 111Ag within the ADMIRAL project. Using the formalism introduced by the MIRD, S-values are calculated for a biological cell exposed to different scenarios of activity distributions of 111Ag. The results of dosimetry calculations performed with Geant4, MCNP6 and PHITS Monte Carlo codes are presented and discussed, showing a good mutual agreement and also with the MIRDcell values. These results will be used within the ISOLPHARM project for the planning of in-vitro experiments in 2D cell cultures and 3D tissue-mimicking scaffolds.

1 April 2026 in Journal of Instrumentation
Verified
Journal Article
Open access
DSD. Serafini
D. Serafini
ALA. Leso
A. Leso
AAAlberto Arzenton
Alberto Arzenton
SSS. Spadano
S. Spadano
EBEdoardo Borciani
Edoardo Borciani
AAA. Andrighetto
A. Andrighetto
Targeted Radionuclide Therapy (TRT) is a well-established technique for cancer treatment. In this approach, radionuclides are bound to specific drugs that selectively transport them to the tumor site. Within the ISOLPHARM project, a radiopharmaceutical for TRT based on the innovative radionuclide 111 Ag is currently under development. 111 Ag has a half-life of 7.45 days and decays by emitting both electrons and gamma-rays. The emission of gamma-rays, predominantly at an energy of 342 keV, enables the visualization of 111 Ag using a gamma camera. In this work, we describe a Monte Carlo simulation developed to optimize the design parameters of such an imaging device. The simulation is based on the Geant4 toolkit, which accurately models the interactions between particles and matter. The estimated spatial resolution and sensitivity of the system are approximately 4 mm and 19 cps/MBq, respectively. The simulated device is able to resolve lesions with a lesion-to-background activity ratio of 4:1 under in-vivo-like conditions. These results indicate that the proposed gamma camera can provide cost-effective imaging capabilities for preclinical radiopharmaceutical studies.

11 July 2025 in The European Physical Journal Special Topics
Verified
Journal Article
Closed access
PDF file
AAAlberto Arzenton
Alberto Arzenton
ALAurora Leso
Aurora Leso
DSDavide Serafini
Davide Serafini
EMEmilio Mariotti
Emilio Mariotti
MLMarcello Lunardon
Marcello Lunardon
AAAlberto Andrighetto
Alberto Andrighetto

1 October 2026 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
ALAurora Leso
Aurora Leso
ASAngeliki Stamatelatou
Angeliki Stamatelatou
ELEfthimis Lamprou
Efthimis Lamprou
EFEleftherios Fysikopoulos
Eleftherios Fysikopoulos
AAAlberto Arzenton
Alberto Arzenton
MAMattia Asti
Mattia Asti
This study aims to quantitatively evaluate the imaging performance of 111Ag in a preclinical planar SPECT system, with emphasis on scatter correction optim

12 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DSDavide Serafini
Davide Serafini
JAJessica Carolina Delgado Alvarez
Jessica Carolina Delgado Alvarez
ALAurora Leso
Aurora Leso
AAAlberto Arzenton
Alberto Arzenton
DMDevid Maniglio
Devid Maniglio
AAAlberto Andrighetto
Alberto Andrighetto
Existing β-imaging devices typically have a field of view (FOV) of about 0.1 cm2, which is too small for imaging large cell cultures as a whole. To provide a complementary tool in radiopharmaceutical research, the Detector Using Maps for Beta-rays Observations (DUMBO) β-imaging device was developed, featuring lower spatial resolution but a larger FOV and non-invasive imaging capability.The prototype presented in this work consists of two ALICE PIxel DEtector (ALPIDE) chips, providing a total sensitive area of 3 cm x 3 cm. The sample can be positioned with three degrees of freedom, two of which are motorized using commercial stepper actuators. The performance was evaluated through Geant4 simulations and experimental measurements with the medical radionuclide 111Ag. Plastic and hydrogel phantoms were imaged to assess the device response to different sample types.The circular shape of the vials containing aqueous 111Ag solutions, as well as the structure of the plastic phantoms with 1-3 mm-wide channels, were clearly resolved. The simulated spatial resolution, which depends on the distance between source and detector, could reach values as good as 0.3 mm; however, sample preparation limited the experimentally achieved resolution. DUMBO demonstrated stable operation, straightforward sample handling, and clear detection capability for samples with activities of the order of 100 kBq.

3 August 2026 in Applied Radiation and Isotopes
Verified
Journal Article
Open access
DSDavide Serafini
Davide Serafini
JAJessica Carolina Delgado Alvarez
Jessica Carolina Delgado Alvarez
ALAurora Leso
Aurora Leso
AAAlberto Arzenton
Alberto Arzenton
DMDevid Maniglio
Devid Maniglio
AAAlberto Andrighetto
Alberto Andrighetto
Existing β-imaging devices with real-time image reconstruction typically have a field of view (FOV) of about 0.1cm2, which is too small for imaging large cell cultures as a whole. To provide a complementary tool in radiopharmaceutical research, the Detector Using Maps for Beta-rays Observations (DUMBO) β-imaging device was developed, featuring lower spatial resolution but a larger FOV and non-invasive imaging capability. The prototype presented in this work consists of two ALICE PIxel DEtector (ALPIDE) chips, providing a total sensitive area of 3cm × 3cm. The sample can be positioned with three degrees of freedom, two of which are motorized using commercial stepper actuators. The performance was evaluated through Geant4 simulations and experimental measurements with the medical radionuclide 111Ag. Plastic and hydrogel phantoms were imaged to assess the device response to different sample types. The circular shape of the vials containing aqueous 111Ag solutions, as well as the structure of the plastic phantoms with 1-3 mm-wide channels, were clearly resolved. The simulated spatial resolution, which depends on the distance between source and detector, could reach values as good as 0.3mm; however, sample preparation limited the experimentally achieved resolution. DUMBO demonstrated stable operation, straightforward sample handling, and clear detection capability for samples with activities of the order of 100kBq.